urea has been researched along with adamantane in 37 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (5.41) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (24.32) | 29.6817 |
2010's | 21 (56.76) | 24.3611 |
2020's | 5 (13.51) | 2.80 |
Authors | Studies |
---|---|
Maliszewska, H; Skwarski, D | 1 |
Gold, W; Lowary, RL; Moreno, OM; Saffir, AJ; Yankell, SL | 1 |
Hammock, BD; Watanabe, T | 1 |
Hammock, BD; Heirtzler, FR; Kim, IH; Morisseau, C; Nishi, K; Tsai, HJ | 1 |
Eiserich, JP; Hammock, BD; Kim, IH; Kubala, L; Newman, JW; Schmelzer, KR | 1 |
Eiserich, JP; Hammock, BD; Inceoglu, B; Jinks, SL; Kim, IH; Kubala, L; Schmelzer, KR | 1 |
Alkayed, NJ; Falck, JR; Grafe, M; Hammock, BD; Koerner, IP; Luria, A; Morisseau, C; Noppens, R; Tsai, HJ; Zhang, W | 1 |
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Tsai, HJ | 1 |
Hammock, BD; Kasagami, T; Kim, IH; Morisseau, C; Nishi, K; Tsai, HJ | 1 |
Alkayed, NJ; Cao, Z; Iliff, J; Liu, L; Merkel, MJ; Motoki, A; Packwood, WH; Van Winkle, DM | 1 |
Gross, GJ; Nithipatikom, K | 1 |
Hammock, BD; Inceoglu, B; Jones, PD; Liu, JY; Morisseau, C; Rose, TE; Sanborn, JR | 1 |
Fang, G; Wu, S; Xu, M; Zeng, F | 1 |
Anandan, SK; Chen, D; Gless, RD; MacIntyre, DE; Rubanyi, GM; Vincelette, J; Wang, YX; Webb, HK; Zhang, LN | 1 |
Aavula, BR; Anandan, SK; Cases, S; Chen, D; Cheng, Y; Do, ZN; Gless, R; Hammock, BD; Jones, PD; MacIntyre, DE; Mehra, U; Patel, DV; Sabry, J; Tran, V; Vincelette, J; Wang, YX; Waszczuk, J; Webb, HK; Whitcomb, R; White, K; Wong, KR; Zhang, LN | 1 |
Anandan, SK; Chen, D; Do, ZN; Gless, R; MacIntyre, E; Patel, DV; Sabry, J; Tran, V; Webb, HK; Whitcomb, R | 1 |
Grzegorzewicz, AE; Hess, TN; Jackson, M; Jones, V; Kasagami, T; Kim, IH; Lee, RE; Lenaerts, AJ; McNeil, MR; Merzlikin, O; Morisseau, C; North, EJ; Scherman, MS | 1 |
Cheshkov, D; Kovalev, V; Puchnin, K; Vatsouro, I; Zaikin, P | 1 |
Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V | 1 |
Falck, JR; Morisseau, C; Mustafa, SJ; Nayeem, MA; Pradhan, I; Zeldin, DC | 1 |
Chen, H; Feng, TT; Han, JG; Ye, C; Zhang, Y | 1 |
Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
Burmistrov, V; Butov, GM; Hammock, BD; Harris, TR; Lee, KS; Morisseau, C; Shihadih, DS | 1 |
Chiamvimonvat, N; Despa, F; Despa, S; Dong, H; Hammock, BD; Harris, TR; Li, N; Margulies, KB; Sharma, S; Taegtmeyer, H | 1 |
Bagchi, S; Sharma, A; Wadhwa, P | 1 |
Hammock, BD; Hwang, SH; Kim, IH; Lango, J; Liu, JY; Morisseau, C; Tsai, HJ; Watanabe, T | 1 |
Hammock, BD; Kim, IH; Nishi, K; Nishiwaki, H; Park, YK | 1 |
Burmistrov, V; Butov, GM; Dalinger, I; Danilov, D; Hammock, BD; Harris, TR; Morisseau, C; Shkineva, T; Vatsadze, I | 1 |
El Sarha, A; Refaat, R; Sakr, A; Salama, M | 1 |
Cameron, MD; Dong, LB; Lin, L; Rudolf, JD; Ruiz, C; Shen, B | 1 |
Bowyer, SL; Kassiou, M; O'Brien-Brown, J; Reekie, TA; Werry, EL; Wong, ECN | 1 |
Burmistrov, V; Butov, G; Hammock, BD; Harris, TR; Morisseau, C | 1 |
Burmistrov, V; Butov, GM; D'yachenko, V; Hammock, BD; Karlov, D; Morisseau, C | 1 |
Burmistrov, V; Butov, GM; Hammock, BD; Karlov, D; Morisseau, C; Pitushkin, D; Rasskazova, E; Vernigora, A | 1 |
Besseling, PJ; Bovée, DM; de Bree, PM; Dijk, AH; Gerritsen, KG; Gremmels, H; Hoorn, EJ; Joles, JA; Nguyen, ITN; Pieters, TT; Rookmaaker, MB; Verhaar, MC; Willekes, N | 1 |
Jackson, M; Kopál, M; Korduláková, J; Madacki, J | 1 |
Babkov, DA; Bazhenov, SV; Berberova, N; Bondarev, NA; Burmistrov, V; Butov, GM; Golubeva, T; Hammock, BD; Kuznetsov, Y; Manukhov, IV; Morisseau, C; Novoyatlova, US; Osipova, V; Pitushkin, D; Sokolova, EV; Spasov, AA; Vasipov, V | 1 |
1 review(s) available for urea and adamantane
Article | Year |
---|---|
Soluble epoxide hydrolase: a new target for cardioprotection.
Topics: Adamantane; Animals; Cardiomegaly; Cardiotonic Agents; Coronary Disease; Dose-Response Relationship, Drug; Drug Design; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Arrest; Humans; Lauric Acids; Mice; Mice, Knockout; Myocardial Contraction; Myocardial Infarction; Urea | 2009 |
1 trial(s) available for urea and adamantane
Article | Year |
---|---|
Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
Topics: Adamantane; Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epoxide Hydrolases; Female; Half-Life; Humans; Male; Middle Aged; Urea; Young Adult | 2012 |
35 other study(ies) available for urea and adamantane
Article | Year |
---|---|
[Synthesis of derivatives of N-(1-adamantyl)-N'-urea with potential antiviral activity].
Topics: Adamantane; Antiviral Agents; Chemical Phenomena; Chemistry; Urea | 1988 |
Effects of chlorhexidine and four antimicrobial compounds on plaque, gingivitis, and staining in beagle dogs.
Topics: Adamantane; Animals; Chlorhexidine; Dental Plaque; Disinfectants; Dogs; Female; Gingival Crevicular Fluid; Gingivitis; Guanidine; Guanidines; Male; Piperazines; Tooth Discoloration; Urea | 1982 |
Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry.
Topics: Adamantane; Animals; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Epoxide Hydrolases; Male; Microsomes, Liver; Rats; Rats, Inbred F344; Spectrometry, Mass, Electrospray Ionization; Urea | 2001 |
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Topics: 1-Octanol; Adamantane; Amides; Animals; Butyrates; Epoxide Hydrolases; Humans; Mice; Models, Molecular; Solubility; Stereoisomerism; Structure-Activity Relationship; Urea; Water | 2005 |
Soluble epoxide hydrolase is a therapeutic target for acute inflammation.
Topics: Adamantane; Animals; Arachidonic Acids; Blood Pressure; Chromatography, High Pressure Liquid; Cytokines; Dose-Response Relationship, Drug; Epoxide Hydrolases; Immunoblotting; Inflammation; Lipopolysaccharides; Lipoxins; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Prostaglandin-Endoperoxide Synthases; Urea | 2005 |
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Down-Regulation; Drug Therapy, Combination; Enzyme Inhibitors; Epoxide Hydrolases; Lipopolysaccharides; Mice; Pain; Urea | 2006 |
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Topics: Adamantane; Animals; Antipyrine; Autoradiography; Blood-Brain Barrier; Blotting, Western; Capillaries; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epoxide Hydrolases; Immunohistochemistry; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Middle Cerebral Artery; Nerve Tissue Proteins; Stroke; Urea | 2007 |
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Administration, Oral; Animals; Benzoates; Biological Availability; Cats; Cricetinae; Dogs; Epoxide Hydrolases; Humans; Hypotension; In Vitro Techniques; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Models, Molecular; Rats; Recombinant Proteins; Solubility; Species Specificity; Stereoisomerism; Structure-Activity Relationship; Urea | 2007 |
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
Topics: Adamantane; Animals; Cyclohexanes; Dogs; Epoxide Hydrolases; Humans; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Microsomes, Liver; Phenylurea Compounds; Rats; Solubility; Structure-Activity Relationship; Urea | 2007 |
Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Animals; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Female; Gene Deletion; Heart Ventricles; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Time Factors; Urea | 2008 |
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Topics: Adamantane; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Epoxide Hydrolases; Humans; Male; Mice; Morphine; Pain; Piperidines; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship; Urea | 2010 |
β-cyclodextrin as the vehicle for forming ratiometric mercury ion sensor usable in aqueous media, biological fluids, and live cells.
Topics: Adamantane; Animals; beta-Cyclodextrins; Cattle; Cell Survival; Chemistry Techniques, Analytical; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Mercury; Mice; Urea; Water | 2010 |
Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension.
Topics: Adamantane; Administration, Oral; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Epoxide Hydrolases; Hypertension; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Urea; Vasodilation | 2011 |
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
Topics: Adamantane; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin Resistance; Mice; Obesity; Rats; Urea | 2011 |
Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.
Topics: Adamantane; Animals; Antitubercular Agents; Biological Availability; Drug Evaluation, Preclinical; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Urea | 2012 |
Calix[4]tubes: an approach to functionalization.
Topics: Adamantane; Calixarenes; Esters; Magnetic Resonance Spectroscopy; Models, Molecular; Tosyl Compounds; Urea | 2012 |
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Diseases; Hypoglycemic Agents; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Myofibrils; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors; Urea | 2012 |
Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ.
Topics: 8,11,14-Eicosatrienoic Acid; Adamantane; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Benzamides; Benzoates; Butyrates; Enzyme Inhibitors; Epoxide Hydrolases; Female; Gene Silencing; Lauric Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Oxygenases; Phenethylamines; Phenylurea Compounds; PPAR gamma; Pyridines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles; Urea; Vasodilation; Vasodilator Agents | 2013 |
Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.
Topics: Adamantane; Catalytic Domain; Epoxide Hydrolases; Humans; Hydrogen Bonding; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Thermodynamics; Urea | 2014 |
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea | 2014 |
Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Molecular Docking Simulation; Urea | 2014 |
Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model.
Topics: Adamantane; Animals; Animals, Genetically Modified; Calcium; Cardiomegaly; Diabetes Mellitus, Type 2; Disease Models, Animal; Eicosanoids; Epoxide Hydrolases; Heart; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Myocardium; Myocytes, Cardiac; Obesity; Oxidative Stress; Pancreas; Prediabetic State; Rats; Sarcolemma; Urea | 2014 |
3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Bacterial Proteins; Computer-Aided Design; Drug Discovery; Epoxide Hydrolases; Humans; Membrane Transport Proteins; Molecular Docking Simulation; Mycobacterium tuberculosis; Quantitative Structure-Activity Relationship; Tuberculosis; Urea | 2015 |
In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Animals; Epoxide Hydrolases; Humans; Liver; Rats; Urea | 2015 |
Structure-activity relationships of amide-phosphonate derivatives as inhibitors of the human soluble epoxide hydrolase.
Topics: Adamantane; Amides; Enzyme Activation; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Organophosphonates; Protein Binding; Recombinant Proteins; Solubility; Structure-Activity Relationship; Tetrahydronaphthalenes; Urea | 2015 |
1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Drug Stability; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Inhibitory Concentration 50; Isoxazoles; Microsomes; Solubility; Structure-Activity Relationship; Urea | 2015 |
Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
Topics: Adamantane; Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Inflammation; Insulin; Kidney; Liver; Male; Nitriles; Oxidative Stress; Pancreas; Pioglitazone; Pyrrolidines; Rats; Rats, Wistar; Thiazolidinediones; Urea; Vildagliptin | 2016 |
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
Topics: Adamantane; Aminobenzoates; Aminophenols; Anilides; Animals; Anti-Bacterial Agents; Carbamates; Carbon-13 Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Polycyclic Compounds; Proton Magnetic Resonance Spectroscopy; Urea | 2017 |
Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X
Topics: Adamantane; Adenosine Triphosphate; Benzoxazoles; Cell Line; Fluorescent Dyes; Guanidines; Humans; Molecular Structure; Purinergic P2X Receptor Agonists; Purinergic P2X Receptor Antagonists; Quinolinium Compounds; Thiourea; Urea | 2017 |
Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.
Topics: Adamantane; Animals; Catalytic Domain; Drug Stability; Enzyme Assays; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Rats; Urea | 2018 |
Imidazolidine-2,4,5- and pirimidine-2,4,6-triones - New primary pharmacophore for soluble epoxide hydrolase inhibitors with enhanced water solubility.
Topics: Adamantane; Binding Sites; Catalytic Domain; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Imidazolidines; Inhibitory Concentration 50; Molecular Docking Simulation; Pyrimidines; Solubility; Structure-Activity Relationship; Urea | 2020 |
Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors.
Topics: Adamantane; Binding Sites; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Lipids; Molecular Docking Simulation; Protein Binding; Solubility; Stereoisomerism; Structure-Activity Relationship; Urea; Water | 2020 |
A plasma creatinine- and urea-based equation to estimate glomerular filtration rate in rats.
Topics: Adamantane; Angiotensin II; Animals; Creatinine; Dipeptides; Glomerular Filtration Rate; Kidney; Kidney Function Tests; Male; Plasma; Rats; Urea | 2021 |
Mycobacterial Epoxide Hydrolase EphD Is Inhibited by Urea and Thiourea Derivatives.
Topics: Adamantane; Epoxide Hydrolases; Gene Expression Regulation, Bacterial; Humans; Mycobacterium tuberculosis; Phenylurea Compounds; Thioacetazone; Thiourea; Tuberculosis; Urea | 2021 |
Anti-Inflammatory Activity of Soluble Epoxide Hydrolase Inhibitors Based on Selenoureas Bearing an Adamantane Moiety.
Topics: Adamantane; Animals; Anti-Inflammatory Agents; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Lipopolysaccharides; Mice; Nitric Oxide; Organoselenium Compounds; Urea | 2022 |